LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 4 of 15: Mean cell count and mean growth rate across biological replicate 1. - Dataset (ID:20240)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | GSK1059615 | 0.04 | uM | LJP5 | 72 | hr | 1476 | 3955 | 3694 | 1.0706 | 1.1177 |
| SK-BR-3 | GSK1059615 | 0.04 | uM | LJP6 | 72 | hr | 1476 | 3496 | 3694 | 0.9466 | 0.9110 |
| SK-BR-3 | GSK1904529A | 0.04 | uM | LJP6 | 72 | hr | 1476 | 2714 | 3694 | 0.7347 | 0.5580 |
| SK-BR-3 | Omipalisib | 0.04 | uM | LJP6 | 72 | hr | 1476 | 1541 | 3694 | 0.4173 | 0.0291 |
| SK-BR-3 | GSK 690693 | 0.04 | uM | LJP5 | 72 | hr | 1476 | 2607 | 3694 | 0.7059 | 0.5101 |
| SK-BR-3 | GW843682X | 0.04 | uM | LJP6 | 72 | hr | 1476 | 3249 | 3694 | 0.8795 | 0.7993 |
| SK-BR-3 | HG-5-113-01 | 0.04 | uM | LJP5 | 72 | hr | 1476 | 3278 | 3694 | 0.8876 | 0.8127 |
| SK-BR-3 | HG-5-88-01 | 0.04 | uM | LJP6 | 72 | hr | 1476 | 2681 | 3694 | 0.7259 | 0.5434 |
| SK-BR-3 | Imatinib | 0.04 | uM | LJP6 | 72 | hr | 1476 | 3656 | 3694 | 0.9897 | 0.9828 |
| SK-BR-3 | JNK-9L | 0.04 | uM | LJP6 | 72 | hr | 1476 | 2608 | 3694 | 0.7062 | 0.5105 |
| SK-BR-3 | JW-7-24-1 | 0.04 | uM | LJP6 | 72 | hr | 1476 | 2791 | 3694 | 0.7556 | 0.5929 |
| SK-BR-3 | Lapatinib | 0.04 | uM | LJP6 | 72 | hr | 1476 | 1530 | 3694 | 0.4144 | 0.0243 |
| SK-BR-3 | LDN-193189 | 0.04 | uM | LJP5 | 72 | hr | 1476 | 3944 | 3694 | 1.0677 | 1.1127 |
| SK-BR-3 | Linifanib | 0.04 | uM | LJP6 | 72 | hr | 1476 | 4036 | 3694 | 1.0927 | 1.1545 |
| SK-BR-3 | Linsitinib | 0.04 | uM | LJP5 | 72 | hr | 1476 | 2598 | 3694 | 0.7035 | 0.5060 |
| SK-BR-3 | Mitoxantrone | 0.04 | uM | LJP5 | 72 | hr | 1476 | 1493 | 3694 | 0.4043 | 0.0076 |
| SK-BR-3 | Mitoxantrone | 0.04 | uM | LJP6 | 72 | hr | 1476 | 1490 | 3694 | 0.4035 | 0.0063 |
| SK-BR-3 | MK2206 | 0.04 | uM | LJP6 | 72 | hr | 1476 | 3372 | 3694 | 0.9129 | 0.8549 |
| SK-BR-3 | Neratinib | 0.04 | uM | LJP5 | 72 | hr | 1476 | 1348 | 3694 | 0.3651 | -0.0578 |
| SK-BR-3 | Nilotinib | 0.04 | uM | LJP5 | 72 | hr | 1476 | 3812 | 3694 | 1.0319 | 1.0532 |
| SK-BR-3 | Nintedanib | 0.04 | uM | LJP6 | 72 | hr | 1476 | 3824 | 3694 | 1.0352 | 1.0586 |
| SK-BR-3 | NU7441 | 0.04 | uM | LJP5 | 72 | hr | 1476 | 3965 | 3694 | 1.0733 | 1.1222 |
| SK-BR-3 | Dactolisib | 0.04 | uM | LJP5 | 72 | hr | 1476 | 1802 | 3694 | 0.4878 | 0.1467 |
| SK-BR-3 | NVP-TAE684 | 0.04 | uM | LJP6 | 72 | hr | 1476 | 3906 | 3694 | 1.0574 | 1.0956 |
| SK-BR-3 | Palbociclib | 0.04 | uM | LJP6 | 72 | hr | 1476 | 3486 | 3694 | 0.9439 | 0.9065 |